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T wo studies published in this present issue of the Archives of Endocrinology and Metabolism, by Natalia Garcia Basavilbaso (1) and coworkers, as well as the one 
by Cesar Boguszewski and coworkers (2), describe the treatment response in real-life 
of pegvisomant (PEGV) therapy in acromegaly patients, including aspects of safety 
and efficacy.
Taken together, these data reflect the everyday practice results of 184 patients from 
27 dedicated centers from Brazil and Argentina. These two essays are essential and very 
welcomed as they report indeed what is happening in real-life with a compound that, 
in theory, as well as during registration studies, somewhat promised to be efficacious 
in controlling disease activity in virtually all acromegaly patients (3,4). However, as 
was also reported in both older and newer publications from the analyses of data 
coming from the Pfizer Inc Initiated Global, non-interventional safety surveillance 
study of long-term treatment with PEGV (ACROSTUDYtm), the efficacy of PEGV 
in normalizing serum IGF-I levels apparently does not exceed about two-thirds  of 
treated patients (5,6).
In the Argentine study, 43 patients (45%) received PEGV monotherapy, while 41 
(55%) received combination therapy (68.3% with long-acting somatostatin analogs). 
Serum IGF-I levels decreased to normal ranges in “only” 63% of patients after a median 
treatment duration of 27 months, with a daily mean dose of about 12 mg (2). In the 
Brazilian report, PEGV was used as monotherapy in 11% of the cases, while normal 
IGF-I levels were obtained in about 75% of patients (1). Why more patients cannot 
be controlled in the real-life setting of center of excellence? This still remains a very 
significant question. A very important issue, for sure, is that in none of the published 
reports on long-term efficacy data, the maximal allowed dose of PEGV (30 mg daily) 
has been used in those subjects that were not well controlled in their IGF-I levels. Also, 
in both reports in this issue of the Journal, it was observed that the mean and maximal 
dosages of PEGV could have been higher, especially in non-controlled subjects. Data 
from Brazil, e.g., show that normalization of serum IGF-I levels at any point during 
therapy was obtained in 80 (74.1%) patients: 11 (92%) in monotherapy and 69 (71%) 
in combined treatment. The median maximum dose of PEGV in monotherapy was 15 
mg/day and in combined treatment it was 10 mg/day, but these values appeared not 
to be statistically different. The Argentine data mentioned that the prescribed dose of 
PEGV ranged from 20 to 210 mg weekly, which was accompanied by a normalization 
of IGF-I levels in 53 % and 47% of combined and monotherapy treatment respectively, 
and as with the Brazilian data without a significant difference between those two. 
Noteworthy is that the group of patients in the Argentine study not achieving disease 
control, received an average daily dose of 13,9 mg that could have left room for an 
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increase up to 30 mg daily. Although not allowed by 
the label, some patients need more PEGV to have their 
IGF-I levels normalized. That is another lesson that 
ACRODAT thaught us (7). Gathering all the literature 
data and the two studies in this issue, it appears that 
patients who need more PEGV to normalize their 
IGF-I levels have a more aggressive disease, as they 
are younger, have higher baseline IGF-I levels, more 
hypertension, more sleep apnea and diabetes and are 
more overweight. A better understanding of this dose-
efficacy relationship of PEGV might avoid inappropriate 
dosing and prevent serum IGF-I levels from remaining 
unnecessarily uncontrolled. Both studies don’t observe 
much difference between the PEGV doses used in 
the controlled versus the uncontrolled groups, which 
is difficult to interpret since a proper dosing has not 
been used in either of the groups. Therefore, the 
major challenge for advocates of PEGV treatment in 
the coming years must be to instruct clinicians to use 
PEGV in doses that do normalize IGF-I is almost all 
subjects and don’t stop halfway in dose titration.
When safety is concerned, both studies address this 
very well and the data show that the well-known side-
effects of localized lipodystrophy and hepatotoxicity 
do occur and the reported incidence varies with the 
interval between observation of the patients, mostly in 
an outdoor setting. Data from ACROSTUDY probably 
underscore the real incidence because of the wider 
interval between reported visits of 6 months to 1 year 
(5,6). However, all in all, these side effects appear to be 
not frequent or serious enough to prevent large-scale 
use of PEGV in acromegaly patients that really need 
such an effective drug as it remains by far the most 
effective medical treatment available to date. What 
remains important to follow up closely is the potential 
increase in tumor size in patients on PEGV treatment, 
especially in those without concomitant somatostatin 
analog treatment. Both studies mentioned this well and 
in detail. One could conclude that this does happen in 
some subjects with aggressive tumors and that none of 
the treating physicians link it to the use of PEGV, but 
the incidence is very low and well below 5%. 
In conclusion, these two large retrospective studies 
from South America nicely add important real-life data 
to the increasing pile of reports on safety and efficacy 
of PGV in the treatment of acromegaly patients. Both 
again show that proper dosing of PEGV in all patients 
remains a challenge and, for sure, leave room for even 
higher efficacy rates in the future.
Disclosure: SJN and AJvdL have received speakers fees and/or 
grants from Ipsen, Novartis and Pfizer Inc. They are member of 
the advisory board of Crinetics.
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